Filing for approval for a breakthrough sickle cell disease treatment will be made in March
Crispr therapy
said, highlighting the company’s leadership in the competitive medical research field and helping the stock rise.
If approved, process exa-cel from Crispr (code: CRSP) and its partners
Vertex Pharmaceuticals
(VRTX) will be the first US-marketed therapy based on Crispr—a Nobel Prize winning technology rewrite faulty genes. Patients treated once in clinical trials remained free of red blood cell disorderpainful symptoms.
